Tafinlar/Mekinist (dabrafenib/trametinib)

pCPA File Number: 21500

Negotiation Status:

Concluded without agreement

Indication(s):

Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CADTH Project Number:

PC0226

pCPA Engagement Letter Issued:

2021-09-10

Negotiation Process Concluded:

2022-09-30